Piper Jaffray reiterated an Overweight rating on Jazz Pharmaceuticals (NASDAQ: JAZZ), and cut the price target to $186.00 (from $208.00) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS Change Analyst EPS View Analyst PT Change

Jazz Pharmaceuticals (JAZZ) PT Cut to $170 at Canaccord GenuityNovember 10, 2015 10:20 AM Pre-Open Stock Movers 11/10: (OCAT) (MDR) (RAX) Higher; (MHR) (LF) (FTK) Lower (more...)November 10, 2015 9:30 AM Jazz Pharmaceuticals (JAZZ) Reports Topline Miss Related to Delays in Xyrem Refills; Leerink Partners Cuts Price Target to $187 November 10, 2015 8:42 AM Mizuho Securities Downgrades Jazz Pharmaceuticals (JAZZ) to NeutralNovember 10, 2015 6:31 AM After-Hours Stock Movers 11/09: (BLCM) (MDR) (RAX) Higher; (LF) (SGMS) (LGF) (GPS) Lower (more...)November 9, 2015 6:09 PM Jazz Pharmaceuticals (JAZZ) Misses Q3 EPS by 4c, Updates FY GuidanceNovember 9, 2015 4:10 PM Jazz Pharmaceuticals Announces Third Quarter 2015 Financial ResultsNovember 9, 2015 4:06 PM Trading Radar for 11/9: DISH Network (DISH), WhiteWave Foods (WWAV), Caesars (CZR), Plug Power (PLUG), Arch Coal (ACI) ReportNovember 6, 2015 2:39 PM